Breast Cancer News and Research

Latest Breast Cancer News and Research

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

T-DM1 better than standard therapy in controlling breast cancer

A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.

5 Jun 2012

Study detects significant changes in the EEG brain activity patterns during chemotherapy

A Cleveland Clinic study has detected significant changes in the electroencephalogram (EEG) brain activity patterns of patients receiving chemotherapy.

5 Jun 2012

Preoperative breast cancer pain involves an inflammatory process

Researchers from the University of California San Francisco studied a sample of women scheduled for breast cancer surgery and sought to determine the occurrence rate for preoperative breast pain, describe characteristics of the pain, evaluate the demographic and clinical variation in the women with preoperative pain, and assess the role of in pro-and anti inflammatory cytokine genes.

5 Jun 2012

BroadcastMed to highlight new AMIGO suite at Brigham and Women's Hospital

BroadcastMed is proud to highlight the new Advanced Multimodality Image Guided Operating Room (AMIGO) suite at Brigham and Women's Hospital. AMIGO is the nation's first fully-integrated operating suite to offer intra-procedural access to an extensive range of advanced imaging modalities.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

5 Jun 2012

High doses of ginseng more effectively reduce cancer-related fatigue in patients

High doses of the herb American ginseng (Panax quinquefolius) over two months reduced cancer-related fatigue in patients more effectively than a placebo, a Mayo Clinic-led study found. Sixty percent of patients studied had breast cancer. The findings are being presented at the American Society of Clinical Oncology's annual meeting.

5 Jun 2012

Researchers uncover cellular basis for age-related breast cancer vulnerability

It is well-known that the risks of breast cancer increase dramatically for women over the age of 50, but what takes place at the cellular level to cause this increase has been a mystery. Some answers and the possibility of preventative measures in the future are provided in a new study by researchers at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory.

5 Jun 2012

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Those cups of coffee that you drink every day to keep alert appear to have an extra perk - especially if you're an older adult. A recent study monitoring the memory and thinking processes of people older than 65 found that all those with higher blood caffeine levels avoided the onset of Alzheimer's disease in the two-to-four years of study follow-up. Moreover, coffee appeared to be the major or only source of caffeine for these individuals.

5 Jun 2012

Androgen receptor an additional hormonal target in many breast cancers

Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) receptor is an additional hormonal target in many breast cancers. Block AR+ breast cancer's ability to access androgen and you block the cancer's ability to survive.

5 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2012

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

4 Jun 2012

Variation in microRNAs may explain survival differences in breast cancer

Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American and Caucasian patients.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

GE Healthcare signed an agreement with Affibody AB to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

4 Jun 2012

Breast Cancer News and Research

Latest Breast Cancer News and Research

New immune response data from Generex’s AE37 Phase II trial on breast cancer

T-DM1 better than standard therapy in controlling breast cancer

Study detects significant changes in the EEG brain activity patterns during chemotherapy

Preoperative breast cancer pain involves an inflammatory process

BroadcastMed to highlight new AMIGO suite at Brigham and Women's Hospital

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Alnylam announces results from ALN-VSP Phase I study on liver cancers

High doses of ginseng more effectively reduce cancer-related fatigue in patients

Researchers uncover cellular basis for age-related breast cancer vulnerability

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Androgen receptor an additional hormonal target in many breast cancers

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Variation in microRNAs may explain survival differences in breast cancer

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

Industry Focus eBook - Oncology (1st Edition) eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Breast Cancer News and Research

Latest Breast Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in